Current report
Open the filing on sec.gov
GT Biopharma, Inc. (GTBP)
Nasdaq: GTBP · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 1995
The companyfiscal 2020, as filed
Revenue$0.00
Net income-$28.3M+26.8%
Earnings per sharen/a
Operating cash flow-$7.3M-98.5%
Cash$5.3M+18817.9%
Debtn/a
Shareholders’ equity-$27.5M
Shares, diluted4,385,222-99.9%
Return on equity-490.0%
The recordfrom its filings
Filings in 202635
Newest filingNov 12 · 8-K
Annual reportMar 2, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted12
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$4.8MCash from operations -$14.4Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Registration effective
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Listing registration
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
Private placement notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.